Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading Volume

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw an uptick in trading volume on Monday . 24,215 shares changed hands during trading, a decline of 16% from the previous session’s volume of 28,850 shares.The stock last traded at $8.86 and had previously closed at $8.04.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Friday, September 20th.

Aligos Therapeutics Price Performance

The stock has a 50 day simple moving average of $12.72 and a two-hundred day simple moving average of $15.70. The company has a market capitalization of $688.93 million, a price-to-earnings ratio of -6.92 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The firm had revenue of $1.06 million during the quarter. During the same period last year, the company earned ($10.75) earnings per share. Equities research analysts predict that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds have recently modified their holdings of ALGS. Armistice Capital LLC acquired a new position in Aligos Therapeutics during the fourth quarter worth $4,538,000. Altitude Crest Partners Inc. purchased a new position in Aligos Therapeutics during the 4th quarter valued at about $1,889,000. Opaleye Management Inc. acquired a new position in Aligos Therapeutics during the fourth quarter worth about $861,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock valued at $644,000 after purchasing an additional 98,628 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).